CagriSema is not approved, so Medicare does not cover it. Here are the three routes after the FDA decides: the $50 Medicare GLP-1 Bridge, regular Part D, or the CagriSema cost without insurance.
Novo’s own head-to-head could not show CagriSema was as good as tirzepatide. I take Zepbound myself, and I go through both sets of numbers, plus the three brand names Novo has registered, including Wegovamy.
An ApoB of 60 mg/dL sits at about the 10th percentile of untreated American adults, lower than roughly nine of every ten, under even the goal the 2026 guideline reserves for its high-risk patients, and inside the range the longevity crowd treats as the destination. By every framework I can find, a 60 is a
An ApoB of 90 mg/dL is the most average result an American adult can get. ApoB is in effect a particle count: every particle that can push cholesterol into an artery wall carries exactly one copy of it. In the National Lipid Association’s percentile table for untreated US adults, 90 is the 50th percentile. Whether
My first ApoB result was 95 mg/dL, in May 2025. Labcorp flagged it high, because Labcorp’s reference range tops out at 90. Cleveland Clinic publishes a normal range for men of 66 to 133, so the same tube of blood at a different lab would have come back with no flag at all. Whether my
I priced one standalone ApoB test at thirteen services on the same day. The advertised prices start at $11; the checkout totals mostly start at $24.
I have three Thorne products in my cabinet. Here is what the P&G Thorne acquisition actually changes, based on the brands bought before it.
The FDA’s compounding committee voted on seven peptides, recommending BPC-157. What peptides are, why the market exploded, and what the vote does and does not decide.
I lift, track my labs, and read the studies. I still ended up with a cabinet full of maybes, while my wife just buys the one gummy she likes at Target. So I stopped asking which ones work and started asking who got paid when I bought them. I cleaned out my medicine cabinet last
BPC-157 promises what an aging body wants most: faster healing, less pain, a return to the version of you that bounced back. It has almost no human evidence behind it. People are sure it works anyway, and in July an FDA committee votes on whether to let pharmacies make it.
